Company intelligence / Profile preview

OPNET Technologies

Santa Monica, California, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Opiant Pharmaceuticals is a specialty biopharmaceutical company focused on developing medicines for addiction and drug overdose. The company is best known for developing the Narcan (naloxone) nasal spray, which was licensed to and commercialized by Emergent BioSolutions for the emergency treatment of opioid overdose. Opiant's pipeline includes OPNT003, a nasal nalmefene formulation designed to treat synthetic opioid overdoses, such as those involving fentanyl. In March 2023, Opiant was acquired by Indivior to strengthen its leadership in addiction treatment.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculeDevice
Industry: Biotech

Partnerships

Emergent BioSolutionsNational Institute on Drug Abuse (NIDA)Biomedical Advanced Research and Development Authority (BARDA)

Beyond the preview

Go deeper on OPNET Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OPNET Technologies.

Explore the full profile